Motif Bio PLC (MTFB) Received “Corporate” Rating from Northland Securities

Motif Bio PLC (MTFB) Received “Corporate” Rating from Northland Securities

Northland Securities reissued their corporate rating on shares of Motif Bio PLC (LON:MTFB) in a research note issued to investors on Friday morning.

Several other brokerages have also commented on MTFB. Beaufort Securities restated a speculative buy rating and set a GBX 110 ($1.41) price target on shares of Motif Bio PLC in a research note on Wednesday, May 3rd. FinnCap restated a buy rating and set a GBX 125 ($1.61) price target on shares of Motif Bio PLC in a research note on Tuesday, May 30th.

Shares of Motif Bio PLC (MTFB) traded up 1.08% during mid-day trading on Friday, hitting GBX 32.85. 4,277,744 shares of the stock were exchanged. Motif Bio PLC has a 12 month low of GBX 21.44 and a 12 month high of GBX 68.25. The stock’s 50 day moving average is GBX 34.19 and its 200 day moving average is GBX 27.52. The firm’s market cap is GBX 64.35 million.

Motif Bio PLC Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:MTFB”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment